Mouse & Rat Model of Bleomycin-Induced Lung Fibrosis
Bleomycin-induced pulmonary fibrosis is the most common experimental study model of human lung fibrosis. Our scientists have developed both a mouse and rat model of bleomycin-induced lung fibrosis and established time courses of effect over a 28-day period post-bleomycin administration.
We have the capability to administer compounds by multiple routes (e.g., oral, inhalation, intravenous, subcutaneous), and efficacy is then monitored by a number of methods:
- Histopathology and qualification via a modified Ashcroft score (n=10)
- Collagen quantification (directly or via image analysis of lung sections)
- Bronchoalveolar fluid (BALF) analysis (separate group of n=10) with leukocyte differential counts
- Biomarker analysis (gene, protein expression patterns)
Fibrosis (assessed by lung pathology and hydroxyproline content) has been assessed over a 28-day time-course; end time-point can be selected to meet experimental aim (day 21 is typical). Bronchoalveolar fluid (BALF) analysis of cellularity and inflammatory mediator content as well as in-life lung function assessment can also be conducted.
Bleomycin elicits a significant increase in BALF cell influx. Cellular kinetics vary according to cell type.
Significant increase in mean Ashcroft score observed following bleomycin treatment. Fibrosis and inflammation incidence scores are also captured (not shown) enabling detection of trends.
Significant increase in mean hydroxyproline observed following bleomycin treatment. Hydroxyproline is quantified using an LCMS analytical method which provides improved sensitivity/reproducibility compared with the standard colorimetric method.